Boehringer Ingelheim Pharma Gmbh & ... vs / on 21 January, 2020
using, offering
for sale, selling, importing and / or exporting the medicinal product,
Linagliptin in any form whatsoever including Linagliptin formulation,
“Linagliptin Tablet” and /or “Linagliptin ... infringement of its product patent “Linagliptin” by the defendant.
2. On receipt of the suit summon, the defendant has filed
written statement, wherein